0000950170-22-017129.txt : 20220812 0000950170-22-017129.hdr.sgml : 20220812 20220812161826 ACCESSION NUMBER: 0000950170-22-017129 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220812 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220812 DATE AS OF CHANGE: 20220812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Imago BioSciences, Inc. CENTRAL INDEX KEY: 0001623715 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 454915810 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40604 FILM NUMBER: 221160372 BUSINESS ADDRESS: STREET 1: 329 OYSTER POINT BLVD., 3RD FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (415) 529-5055 MAIL ADDRESS: STREET 1: 329 OYSTER POINT BLVD., 3RD FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 imgo-20220812.htm 8-K 8-K
false000162371500016237152022-08-122022-08-12

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2022

 

 

Imago BioSciences, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

Delaware

001-40604

45-4915810

(State or other jurisdiction
of incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

329 Oyster Point Blvd. 3rd Floor

South San Francisco, California 94080

(Address of principal executive offices, including Zip Code)

 

Registrant’s telephone number, including area code: (415) 529-5055

 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

IMGO

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 



 

 

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2022, Imago BioSciences, Inc. issued a press release announcing its financial results as of and for the quarter ended June 30, 2022. The press release is being furnished as Exhibit 99.1.

 

The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

 

Description

99.1

 

Press Release dated August 12, 2022

104

 

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

IMAGO BIOSCIENCES, INC.

 

 

 

 

Date:

August 12, 2022

By:

/s/ Hugh Y. Rienhoff, Jr., M.D.

 

 

 

Hugh Y. Rienhoff, Jr., M.D.

 

 

 

Chief Executive Officer

 


EX-99.1 2 imgo-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

img230188249_0.jpg 

Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates

 

- Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia (ET) Presented at European Hematology Association (EHA) Meeting 2022 -

 

- Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis Presented at EHA 2022 -

 

- First Participant Dosed in Investigator-Sponsored Phase 1/2 Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung Cancer -

 

-
Obtained Advice from FDA Clinical Outcomes Assessment (COA) Group with Regard to Patient Reported Outcome (PRO) Endpoints for the Company’s Planned Phase 3 Trial of Bomedemstat in ET Patients -

 

SOUTH SAN FRANCISCO, Calif. – August 12, 2022 – Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today reported financial results for the second quarter ended June 30, 2022 and provided business updates.

 

“We were delighted to present updated positive data on our Phase 2 trial of bomedemstat in essential thrombocythemia (ET) at EHA in June. In our updated dataset, bomedemstat demonstrated hematologic and symptomatic improvement in ET patients and, importantly, demonstrated the durability of these hematologic responses. These data will support our ongoing discussions with the FDA, as we target an End of Phase 2 meeting with the FDA later this year, and move towards initiating the pivotal trial,” said Hugh Young Rienhoff, Jr., M.D, Chief Executive Officer of Imago. “At EHA, we also presented positive data from our advanced myelofibrosis (MF) Phase 2 trial where bomedemstat demonstrated improvements in total symptom scores, fibrosis grades, spleen volumes and anemia, as well as reductions in mutant allele frequencies. Looking ahead, we plan to evaluate bomedemstat in combination with ruxolitinib in MF patients in a trial starting in the Fall 2022. Lastly, in addition to our long-held

 


Exhibit 99.1

plans to study bomedemstat in other myeloproliferative neoplasms, such as polycythemia vera, we were pleased to see initiation of the first solid tumor clinical study of bomedemstat, an investigator-sponsored study of bomedemstat in combination with atezolizumab for small cell lung cancer.”

 

Second Quarter 2022 and Subsequent Highlights

 

Presented Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at EHA 2022. In June 2022, Imago presented updated positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with ET. As of the data cutoff date of 29 April 2022: bomedemstat demonstrated normalization of platelets in the absence of new thromboembolic events (the primary efficacy endpoint of this study) in 94% of patients; as well as durability of hematologic response with 81% of patients achieving normalized platelet counts for at least 12 weeks (ELN criteria defining a durable response in ET); 58% of patients treated with bomedemstat experienced symptomatic improvement (defined as a decrease in Total Symptom Score) at 24 weeks; and both JAK2 and CALR mutation burdens were decreased during treatment with bomedemstat. As of the data cutoff date, the most common adverse events (AEs) were dysgeusia, fatigue, constipation, and arthralgia. Twelve patients reported a total of 19 serious adverse events (SAEs) with six deemed related to bomedemstat by the investigator. There have been no dose limiting toxicities (DLTs) or deaths related to drug. The EHA data cut represented the last presentation before the End-of-Phase 2 meeting with FDA expected later this year.

 

Presented Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at EHA 2022. In June 2022, the Company presented updated positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with MF. As of the data cutoff date of 29 April 2022, in addition to improvements in the standard metrics of spleen volume reduction and symptom scores, long term treatment with bomedemstat showed: 52% of evaluable patients had reductions in mutant allele frequencies, including ASXL1; 85% of evaluable patients demonstrated improved or stable fibrosis scores; and 90% of patients who were transfusion independent at baseline had stable or improved hemoglobin. The most common non-hematologic AE was dysgeusia. Of 14 drug related SAEs, 5 were Grade 2, 8 Grade 3 and 1 Grade 4 (thrombocytopenia). There have been no DLTs or deaths related to drug. Eligible MF patients completing this Phase 2 study have rolled into an extension study to evaluate the longer-term safety and impact of bomedemstat on the natural history of MF. Imago plans to commence an investigator-sponsored evaluation of bomedemstat in combination with ruxolitinib in

 


Exhibit 99.1

patients with MF who have a sub-optimal response to JAK inhibition or are treatment naïve in the Fall 2022.

 

Announced First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung Cancer, the first clinical study of Bomedemstat in patients with Solid Tumors. In May 2022, Imago announced that the first participant had been treated in an investigator-sponsored Phase 1/2 study of bomedemstat in combination with atezolizumab (Tecentriq®) during the maintenance phase of treatment in people newly diagnosed with extensive stage small cell lung cancer (ES-SCLC). The Phase 1/2 open-label study will enroll approximately 30 participants diagnosed with ES-SCLC to establish the safety and tolerability of a combination treatment with bomedemstat and atezolizumab. The study is being conducted in Seattle and led by Rafael Santana-Davila, M.D., associate professor at the University of Washington School of Medicine and Joseph Hiatt, M.D., Ph.D., of Fred Hutchinson Cancer Center (“Fred Hutch”), and in collaboration with the National Cancer Institute (NCI) funded Fred Hutch Lung Specialized Project of Research Excellence.

 

Completed Enrollment in Phase 2 Study of Bomedemstat in Essential Thrombocythemia. In May 2022, Imago announced the completion of enrollment for the Phase 2 clinical study of bomedemstat for the treatment of ET with 73 patients enrolled, exceeding the initial target enrollment of 60 patients. This study is designed to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of bomedemstat, an oral lysine-specific demethylase 1 (LSD1) inhibitor, in patients with ET who have failed at least one standard therapy.

 

Obtained Advice from FDA Clinical Outcomes Assessment (COA) Group with Regard to Patient Reported Outcome (PRO) Endpoints for the Company’s Planned Phase 3 Trial of Bomedemstat in ET Patients. In June 2022, Imago discussed with FDA the proposed instruments to assess patient-reported symptoms and outcomes for key secondary endpoints.

Anticipated Upcoming Milestones

End-of-Phase 2 meeting with FDA for bomedemstat in ET expected this year

 

Anticipate initiating investigator-sponsored Phase 2 combination study of bomedemstat with ruxolitinib in MF in the Fall 2022

 


Exhibit 99.1

 

Expect data updates for the bomedemstat Phase 2 trials in ET and MF at the American Society of Hematology (ASH) Annual Meeting in December 2022

 

Second Quarter 2022 Financial Results

Cash, Cash Equivalents and Short-term Investments: As of June 30, 2022, Imago had cash, cash equivalents and short-term investments of $190.0 million, compared to $217.4 million as of December 31, 2021. Based on current operating plans, management believes cash runway extends into 2025.

 

Research & Development (R&D) Expenses: R&D expenses for the quarter ended June 30, 2022 were $9.7 million (including stock-based compensation expense of $0.7 million), compared to $7.1 million for the same period in 2021. The overall increase in R&D expenses was primarily related to the commencement of a Phase 2 extension study started in the second half of 2021 for the long-term follow-up of patients from MF and ET clinical trials, and salaries and non-cash stock-based compensation expense for R&D employees as we ramped up our operations.

 

General and Administrative (G&A) Expenses: G&A expenses for the quarter ended June 30, 2022 were $4.3 million (including stock-based compensation expense of $1.0 million), compared to $1.7 million for the same period in 2021. The increase was primarily due to increases in professional fees attributable to accounting, legal, audit, and insurance expenses associated with public company operations and compensation and personnel-related costs, including stock-based compensation expense, as a result of increased headcount.

 

Net Loss: Net loss for the quarter ended June 30, 2022 was $13.7 million, compared to $8.8 million for the same period in 2021.

###

 

About Imago BioSciences

 

Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is

 


Exhibit 99.1

focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, European Medicines Agency (EMA) Orphan Designation for the treatment of ET and MF, and PRIority MEdicines (PRIME) Designation by the EMA for the treatment of MF. The company is based in South San Francisco, California. To learn more, visit www.imagobio.com, www.myelofibrosisclinicalstudy.com, www.etclinicalstudy.com and follow us on Twitter @ImagoBioRx, Facebook and LinkedIn.

 

Forward Looking Statements

 

This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “may,” “will,” “should,” “expect,” “believe” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.

 

These statements may relate to, but are not limited to, the results, conduct, progress and timing of Imago clinical trials, timing of data presentations, the regulatory approval path for bomedemstat, plans for future operations, and expected cash runway, as well as assumptions relating to the foregoing. Forward looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Important factors that could affect future results and cause those results to differ materially from those expressed in the forward-looking statements include: our limited operating history and lack of products for commercial sale; our significant losses since inception and for the foreseeable future; our need for substantial additional financing; our unpredictable operating results, due to, for example, general economic conditions in the United States and abroad; our business’s dependence on development, regulatory approval and commercialization of our product candidates; difficulties in enrolling patients and risks of substantial delays in our clinical trials; our minimal control over product candidates in investigator-initiated clinical trials; uncertainties in the cost and outcomes of our clinical studies and the acceptance for presentation at medical meetings of data from our clinical studies; uncertainties in the regulatory review and approval of our product candidates if our pivotal studies are positive; potentially material changes to the interim, top-line and preliminary data from our clinical trials; potential undesirable effects of our product candidates and safety or supply issues, in each case with respect to our product candidates alone or in combination with other compounds or products; our potential inability to obtain and maintain orphan drug designation and delays in approvals despite Fast Track designation; risks related to clinical trials outside of the United States; our need to manufacture multiple batches of bomedemstat using a commercial current Good Manufacturing Practice; risks related to

 


Exhibit 99.1

COVID-19 or other pandemics, natural disasters and wars; risks related to competition; difficulties in expanding our organization and managing growth, attracting and retaining senior management and key scientific personnel and establishing sales and other commercialization functions; risks related to information technology system and cybersecurity; risks related to misconduct of our employees and independent contractors; risks related to hazardous materials and our compliance with environmental laws and regulations; risks related to litigation and other claims; risks related to reliance on third parties to conduct and support preclinical studies and clinical trials, and to manufacture our product candidates; risks related to third-party intellectual property infringement claims and our ability to protect our own intellectual property; risks related to governmental policies and regulations including with respect to drug prices and reimbursement, and changes thereof; risks related to our common stock; risks related to our public company, “emerging growth company” and “smaller reporting company” status; risks related to material weaknesses and failure to maintain effective internal control over financial reporting; and other risks and uncertainties, including those listed in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 and our subsequent quarterly reports. You should not put undue reliance on any forward-looking statements. Forward looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved, if at all.

 

Except as required by law, Imago does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

 

Contacts:

Media Contact:
Will Zasadny
Canale Communications
will.zasadny@canalecomm.com

 

Investor Contact:

Laurence Watts

Gilmartin Group, LLC.

Laurence@gilmartinir.com

 


Exhibit 99.1

IMAGO BIOSCIENCES, INC.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

(unaudited)

 

 

 

JUNE 30,

 

 

DECEMBER 31,

 

 

 

2022

 

 

2021

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

22,772

 

 

$

11,226

 

Short-term investments

 

 

167,238

 

 

 

206,184

 

Prepaid expenses and other current assets

 

 

2,562

 

 

 

3,894

 

Total current assets

 

 

192,572

 

 

 

221,304

 

Property and equipment, net

 

 

3

 

 

 

2

 

Other long-term assets

 

 

3,536

 

 

 

3,480

 

Total assets

 

$

196,111

 

 

$

224,786

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

2,584

 

 

$

3,459

 

Accrued and other current liabilities

 

 

6,189

 

 

 

6,633

 

Total current liabilities

 

 

8,773

 

 

 

10,092

 

Commitments and contingencies

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Common stock, $0.0001 par value; 300,000,000 shares authorized as of both June 30, 2022 and December 31, 2021; 33,737,873 and 33,531,743 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively

 

 

3

 

 

 

3

 

Additional paid-in capital

 

 

330,951

 

 

 

327,387

 

Accumulated other comprehensive loss

 

 

(828

)

 

 

(43

)

Accumulated deficit

 

 

(142,788

)

 

 

(112,653

)

Total stockholders’ equity

 

 

187,338

 

 

 

214,694

 

Total liabilities and stockholders’ equity

 

$

196,111

 

 

$

224,786

 

 

 


Exhibit 99.1

IMAGO BIOSCIENCES, INC.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

(unaudited)

 

 

 

THREE MONTHS ENDED

 

 

SIX MONTHS ENDED

 

 

 

JUNE 30,

 

 

JUNE 30,

 

 

 

2022

 

2021

 

 

2022

 

2021

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

9,677

 

$

7,099

 

 

$

22,179

 

$

11,871

 

General and administrative

 

 

4,339

 

 

1,743

 

 

 

8,350

 

 

4,119

 

Total operating expenses

 

 

14,016

 

 

8,842

 

 

 

30,529

 

 

15,990

 

Loss from operations

 

 

(14,016

)

 

(8,842

)

 

 

(30,529

)

 

(15,990

)

Other income (expense), net:

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

148

 

 

82

 

 

 

212

 

 

169

 

Other income (expense), net

 

 

127

 

 

(46

)

 

 

182

 

 

(94

)

Total other income, net

 

 

275

 

 

36

 

 

 

394

 

 

75

 

Net loss

 

$

(13,741

)

$

(8,806

)

 

$

(30,135

)

$

(15,915

)

Net loss per share, basic and diluted

 

$

(0.41

)

$

(8.13

)

 

$

(0.89

)

$

(15.06

)

Weighted-average shares used in computing net loss per share, basic and diluted

 

 

33,735,785

 

 

1,082,932

 

 

 

33,691,163

 

 

1,056,624

 

 

 


GRAPHIC 3 img230188249_0.jpg GRAPHIC begin 644 img230188249_0.jpg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end EX-101.LAB 4 imgo-20220812_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Ex Transition Period Entity Ex Transition Period Amendment Flag Amendment Flag Entity Incorporation State Country Code Entity Incorporation, State or Country Code City Area Code City Area Code Document Period End Date Document Period End Date Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity File Number Entity File Number Entity Address, Address Line One Entity Address, Address Line One Entity Tax Identification Number Entity Tax Identification Number Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Pre Commencement Tender Offer Pre-commencement Tender Offer Security 12b Title Title of 12(b) Security Entity Address, State or Province Entity Address, State or Province Document Type Document Type Written Communications Written Communications Security Exchange Name Security Exchange Name Entity Address, Address Line Two Entity Address, Address Line Two Entity Central Index Key Entity Central Index Key Local Phone Number Local Phone Number Pre Commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover [Abstract] Cover [Abstract] Trading Symbol Trading Symbol EX-101.PRE 5 imgo-20220812_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 6 imgo-20220812.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information
Aug. 12, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001623715
Document Type 8-K
Document Period End Date Aug. 12, 2022
Entity Registrant Name Imago BioSciences, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-40604
Entity Tax Identification Number 45-4915810
Entity Address, Address Line One 329 Oyster Point Blvd.
Entity Address, Address Line Two 3rd Floor
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (415)
Local Phone Number 529-5055
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol IMGO
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 8 imgo-20220812_htm.xml IDEA: XBRL DOCUMENT 0001623715 2022-08-12 2022-08-12 false 0001623715 8-K 2022-08-12 Imago BioSciences, Inc. DE 001-40604 45-4915810 329 Oyster Point Blvd. 3rd Floor South San Francisco CA 94080 (415) 529-5055 false false false false Common Stock, par value $0.0001 per share IMGO NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports imgo-20220812.htm imgo-20220812.xsd imgo-20220812_lab.xml imgo-20220812_pre.xml imgo-ex99_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "imgo-20220812.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "imgo-20220812.htm" ] }, "labelLink": { "local": [ "imgo-20220812_lab.xml" ] }, "presentationLink": { "local": [ "imgo-20220812_pre.xml" ] }, "schema": { "local": [ "imgo-20220812.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "imgo", "nsuri": "http://imagobio.com/20220812", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "imgo-20220812.htm", "contextRef": "C_d7fb855a-9c77-4790-9f4f-1973f4e0bdb6", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "imgo-20220812.htm", "contextRef": "C_d7fb855a-9c77-4790-9f4f-1973f4e0bdb6", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://imagobio.com/20220812/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0000950170-22-017129-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-017129-xbrl.zip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end